Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 8, 2011, Pages 1927-1932

  Chen, Po Yu ^a   Huang, Ming Chyi ^a,b   Chiu, Chih Chiang ^a,b   Liu, Hsing Cheng ^a,b   Lu, Mong Liang ^b,c   Chen, Chun Hsin ^b,c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

High molecular weight adiponectin; Insulin resistance; Metabolic syndrome; Retinol binding protein 4; Schizophrenia

Indexed keywords

ADIPONECTIN; CLOZAPINE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MOLECULAR WEIGHT; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; BODY MASS INDEX; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RETINOL-BINDING PROTEINS, PLASMA; SCHIZOPHRENIA; WAIST CIRCUMFERENCE;

EID: 84860410703     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.07.014     Document Type: Article

References (63)

1. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
2. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
3. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004, 65:1335-1342.
4. Bai Y.M., Chen J.Y., Yang W.S., Chi Y.C., Liou Y.J., Lin C.C., et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry 2007, 68:1834-1839.
5. Bai Y.M., Chen T.T., Yang W.S., Chi Y.C., Lin C.C., Liou Y.J., et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009, 111:1-8.
6. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007, 90:162-173.
7. Chavez A.O., Coletta D.K., Kamath S., Cromack D.T., Monroy A., Folli F., et al. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. Am J Physiol Endocrinol Metab 2009, 296:E758-E764.
8. Chen C.H., Lu M.L., Kuo P.H., Chen P.Y., Chiu C.C., Kao C.F., et al. Gender differences in the effects of peroxisome proliferator-activated receptor gamma2 gene polymorphisms on metabolic adversity in patients with schizophrenia or schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:239-245.
9. Cho Y.M., Youn B.S., Lee H., Lee N., Min S.S., Kwak S.H., et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29:2457-2461.
10. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 2004, 61:75-80.
11. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004, 49:753-760.
12. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006, 83:87-93.
13. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009, 194:434-438.
14. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001, 98:2005-2010.
15. Fujimatsu D., Kotooka N., Inoue T., Nishiyama M., Node K. Association between high molecular weight adiponectin levels and metabolic parameters. J Atheroscler Thromb 2009, 16:553-559.
16. Graham T.E., Yang Q., Bluher M., Hammarstedt A., Ciaraldi T.P., Henry R.R., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-2563.
17. Hagg S., Lindblom Y., Mjorndal T., Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006, 21:93-98.
18. Haider D.G., Schindler K., Prager G., Bohdjalian A., Luger A., Wolzt M., et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007, 92:1168-1171.
19. Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Reginster J.Y., et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008, 106:308-314.
20. Hara K., Horikoshi M., Yamauchi T., Yago H., Miyazaki O., Ebinuma H., et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29:1357-1362.
21. Heliovaara M.K., Remitz A., Reitamo S., Teppo A.M., Karonen S.L., Ebeling P. 13-cis-Retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration. Metabolism 2007, 56:786-791.
22. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006, 20:75-79.
23. Huang M.C., Lu M.L., Tsai C.J., Chen P.Y., Chiu C.C., Jian D.L., et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009, 120:274-280.
24. Hulthe J., Hulten L.M., Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003, 52:1612-1614.
25. Janke J., Engeli S., Boschmann M., Adams F., Bohnke J., Luft F.C., et al. Retinol-binding protein 4 in human obesity. Diabetes 2006, 55:2805-2810.
26. Kazumi T., Kawaguchi A., Hirano T., Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 2004, 53:589-593.
27. Koistinen H.A., Remitz A., Gylling H., Miettinen T.A., Koivisto V.A., Ebeling P. Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diabetes Metab Res Rev 2001, 17:391-395.
28. Kotidis E.V., Koliakos G.G., Baltzopoulos V.G., Ioannidis K.N., Yovos J.G., Papavramidis S.T. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment-a prospective study. Obes Surg 2006, 16:1425-1432.
29. Laaksonen D.E., Lakka H.M., Niskanen L.K., Kaplan G.A., Salonen J.T., Lakka T.A. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070-1077.
30. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
31. Lara-Castro C., Luo N., Wallace P., Klein R.L., Garvey W.T. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006, 55:249-259.
32. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
33. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580:2917-2921.
34. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
35. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
36. Murashita M., Inoue T., Kusumi I., Nakagawa S., Itoh K., Tanaka T., et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007, 61:54-58.
37. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl 4):8-13.
38. Newcomer M.E., Ong D.E. Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim Biophys Acta 2000, 1482:57-64.
39. Pajvani U.B., Du X., Combs T.P., Berg A.H., Rajala M.W., Schulthess T., et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003, 278:9073-9085.
40. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.
41. Promintzer M., Krebs M., Todoric J., Luger A., Bischof M.G., Nowotny P., et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab 2007, 92:4306-4312.
42. Qi Q., Yu Z., Ye X., Zhao F., Huang P., Hu F.B., et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007, 92:4827-4834.
43. Richards A.A., Hickman I.J., Wang A.Y., Jones A.L., Newell F., Mowry B.J., et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 2006, 26:232-237.
44. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
45. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004, 68:975-981.
46. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008, 101:266-272.
47. Seino Y., Hirose H., Saito I., Itoh H. High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 2007, 56:1493-1499.
48. Seino Y., Hirose H., Saito I., Itoh H. High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism 2009, 58:355-360.
49. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin N., Stip E., et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr Res 2008, 102:329-336.
50. Shim C.Y., Park S., Kim J.S., Shin D.J., Ko Y.G., Kang S.M., et al. Association of plasma retinol-binding protein 4, adiponectin, and high molecular weight adiponectin with insulin resistance in non-diabetic hypertensive patients. Yonsei Med J 2010, 51:375-384.
51. Smith R.C., Lindenmayer J.P., Hu Q., Kelly E., Viviano T.F., Cornwell J., et al. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Schizophr Res 2010, 120:204-209.
52. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007, 24:481-485.
53. Sporn A.L., Bobb A.J., Gogtay N., Stevens H., Greenstein D.K., Clasen L.S., et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005, 44:925-933.
54. Takashima N., Tomoike H., Iwai N. Retinol-binding protein 4 and insulin resistance. N Engl J Med 2006, 355:1392. author reply 4-5.
55. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007, 92:2712-2719.
56. Togo T., Kojima K., Shoji M., Kase A., Uchikado H., Katsuse O., et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 2004, 19:37-40.
57. Ulgen F., Herder C., Kuhn M.C., Willenberg H.S., Schott M., Scherbaum W.A., et al. Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients. Arch Physiol Biochem 2010, 116:57-62.
58. von Eynatten M., Lepper P.M., Liu D., Lang K., Baumann M., Nawroth P.P., et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007, 50:1930-1937.
59. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003, 278:40352-40363.
60. Wampers M., Hanssens L., van Winkel R., Heald A., Collette J., Peuskens J., et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol 2011, 10.1016/j.physletb.2003.10.071.
61. Xu M., Li X.Y., Wang J.G., Wang X.J., Huang Y., Cheng Q., et al. Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population. Diabetologia 2009, 52:1511-1519.
62. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
63. Zhang Z.J., Yao Z.J., Liu W., Fang Q., Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004, 184:58-62.